Novel bumped kinase inhibitors are safe and effective therapeutics in the calf clinical model for cryptosporidiosis

Deborah A. Schaefer, Dana P. Betzer, Kylie D. Smith, Zachary G. Millman, Hannah C. Michalski, Sarah E. Menchaca, Jennifer A. Zambriski, Kayode K. Ojo, Matthew A. Hulverson, Samuel L M Arnold, Kasey L. Rivas, Rama S R Vidadala, Wenlin Huang, Lynn K. Barrett, Dustin J. Maly, Erkang Fan, Wesley C. Van Voorhis, Michael W Riggs

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Cryptosporidiosis, caused by the apicomplexan parasite Cryptosporidium parvum, is a diarrheal disease that has produced a large global burden in mortality and morbidity in humans and livestock. There are currently no consistently effective parasite-specific pharmaceuticals available for this disease. Bumped kinase inhibitors (BKIs) specific for parasite calcium-dependent protein kinases (CDPKs) have been shown to reduce infection in several parasites having medical and veterinary importance, including Toxoplasma gondii, Plasmodium falciparum, and C. parvum. In the present study, BKIs were screened for efficacy against C. parvum infection in the neonatal mouse model. Three BKIs were then selected for safety and clinical efficacy evaluation in the calf model for cryptosporidiosis. Significant BKI treatment effects were observed for virtually all clinical and parasitological scoring parameters, including diarrhea severity, oocyst shedding, and overall health. These results provide proof of concept for BKIs as therapeutic drug leads in an animal model for human cryptosporidiosis.

Original languageEnglish (US)
Pages (from-to)1856-1864
Number of pages9
JournalJournal of Infectious Diseases
Volume214
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Cryptosporidiosis
Cryptosporidium parvum
Phosphotransferases
Parasites
Therapeutics
Oocysts
Toxoplasma
Livestock
Plasmodium falciparum
Infection
Pharmaceutical Preparations
Diarrhea
Animal Models
Morbidity
Safety
Mortality
Health

Keywords

  • Animal model
  • Bumped kinase inhibitor
  • Clinical evaluation
  • CpCDPK-1
  • Cryptosporidiosis
  • Cryptosporidium
  • Oocyst shedding
  • Therapeutic

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Novel bumped kinase inhibitors are safe and effective therapeutics in the calf clinical model for cryptosporidiosis. / Schaefer, Deborah A.; Betzer, Dana P.; Smith, Kylie D.; Millman, Zachary G.; Michalski, Hannah C.; Menchaca, Sarah E.; Zambriski, Jennifer A.; Ojo, Kayode K.; Hulverson, Matthew A.; Arnold, Samuel L M; Rivas, Kasey L.; Vidadala, Rama S R; Huang, Wenlin; Barrett, Lynn K.; Maly, Dustin J.; Fan, Erkang; Van Voorhis, Wesley C.; Riggs, Michael W.

In: Journal of Infectious Diseases, Vol. 214, No. 12, 01.12.2016, p. 1856-1864.

Research output: Contribution to journalArticle

Schaefer, DA, Betzer, DP, Smith, KD, Millman, ZG, Michalski, HC, Menchaca, SE, Zambriski, JA, Ojo, KK, Hulverson, MA, Arnold, SLM, Rivas, KL, Vidadala, RSR, Huang, W, Barrett, LK, Maly, DJ, Fan, E, Van Voorhis, WC & Riggs, MW 2016, 'Novel bumped kinase inhibitors are safe and effective therapeutics in the calf clinical model for cryptosporidiosis', Journal of Infectious Diseases, vol. 214, no. 12, pp. 1856-1864. https://doi.org/10.1093/infdis/jiw488
Schaefer, Deborah A. ; Betzer, Dana P. ; Smith, Kylie D. ; Millman, Zachary G. ; Michalski, Hannah C. ; Menchaca, Sarah E. ; Zambriski, Jennifer A. ; Ojo, Kayode K. ; Hulverson, Matthew A. ; Arnold, Samuel L M ; Rivas, Kasey L. ; Vidadala, Rama S R ; Huang, Wenlin ; Barrett, Lynn K. ; Maly, Dustin J. ; Fan, Erkang ; Van Voorhis, Wesley C. ; Riggs, Michael W. / Novel bumped kinase inhibitors are safe and effective therapeutics in the calf clinical model for cryptosporidiosis. In: Journal of Infectious Diseases. 2016 ; Vol. 214, No. 12. pp. 1856-1864.
@article{87351dacc8114c409b941c26ea2c1e4a,
title = "Novel bumped kinase inhibitors are safe and effective therapeutics in the calf clinical model for cryptosporidiosis",
abstract = "Cryptosporidiosis, caused by the apicomplexan parasite Cryptosporidium parvum, is a diarrheal disease that has produced a large global burden in mortality and morbidity in humans and livestock. There are currently no consistently effective parasite-specific pharmaceuticals available for this disease. Bumped kinase inhibitors (BKIs) specific for parasite calcium-dependent protein kinases (CDPKs) have been shown to reduce infection in several parasites having medical and veterinary importance, including Toxoplasma gondii, Plasmodium falciparum, and C. parvum. In the present study, BKIs were screened for efficacy against C. parvum infection in the neonatal mouse model. Three BKIs were then selected for safety and clinical efficacy evaluation in the calf model for cryptosporidiosis. Significant BKI treatment effects were observed for virtually all clinical and parasitological scoring parameters, including diarrhea severity, oocyst shedding, and overall health. These results provide proof of concept for BKIs as therapeutic drug leads in an animal model for human cryptosporidiosis.",
keywords = "Animal model, Bumped kinase inhibitor, Clinical evaluation, CpCDPK-1, Cryptosporidiosis, Cryptosporidium, Oocyst shedding, Therapeutic",
author = "Schaefer, {Deborah A.} and Betzer, {Dana P.} and Smith, {Kylie D.} and Millman, {Zachary G.} and Michalski, {Hannah C.} and Menchaca, {Sarah E.} and Zambriski, {Jennifer A.} and Ojo, {Kayode K.} and Hulverson, {Matthew A.} and Arnold, {Samuel L M} and Rivas, {Kasey L.} and Vidadala, {Rama S R} and Wenlin Huang and Barrett, {Lynn K.} and Maly, {Dustin J.} and Erkang Fan and {Van Voorhis}, {Wesley C.} and Riggs, {Michael W}",
year = "2016",
month = "12",
day = "1",
doi = "10.1093/infdis/jiw488",
language = "English (US)",
volume = "214",
pages = "1856--1864",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Novel bumped kinase inhibitors are safe and effective therapeutics in the calf clinical model for cryptosporidiosis

AU - Schaefer, Deborah A.

AU - Betzer, Dana P.

AU - Smith, Kylie D.

AU - Millman, Zachary G.

AU - Michalski, Hannah C.

AU - Menchaca, Sarah E.

AU - Zambriski, Jennifer A.

AU - Ojo, Kayode K.

AU - Hulverson, Matthew A.

AU - Arnold, Samuel L M

AU - Rivas, Kasey L.

AU - Vidadala, Rama S R

AU - Huang, Wenlin

AU - Barrett, Lynn K.

AU - Maly, Dustin J.

AU - Fan, Erkang

AU - Van Voorhis, Wesley C.

AU - Riggs, Michael W

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Cryptosporidiosis, caused by the apicomplexan parasite Cryptosporidium parvum, is a diarrheal disease that has produced a large global burden in mortality and morbidity in humans and livestock. There are currently no consistently effective parasite-specific pharmaceuticals available for this disease. Bumped kinase inhibitors (BKIs) specific for parasite calcium-dependent protein kinases (CDPKs) have been shown to reduce infection in several parasites having medical and veterinary importance, including Toxoplasma gondii, Plasmodium falciparum, and C. parvum. In the present study, BKIs were screened for efficacy against C. parvum infection in the neonatal mouse model. Three BKIs were then selected for safety and clinical efficacy evaluation in the calf model for cryptosporidiosis. Significant BKI treatment effects were observed for virtually all clinical and parasitological scoring parameters, including diarrhea severity, oocyst shedding, and overall health. These results provide proof of concept for BKIs as therapeutic drug leads in an animal model for human cryptosporidiosis.

AB - Cryptosporidiosis, caused by the apicomplexan parasite Cryptosporidium parvum, is a diarrheal disease that has produced a large global burden in mortality and morbidity in humans and livestock. There are currently no consistently effective parasite-specific pharmaceuticals available for this disease. Bumped kinase inhibitors (BKIs) specific for parasite calcium-dependent protein kinases (CDPKs) have been shown to reduce infection in several parasites having medical and veterinary importance, including Toxoplasma gondii, Plasmodium falciparum, and C. parvum. In the present study, BKIs were screened for efficacy against C. parvum infection in the neonatal mouse model. Three BKIs were then selected for safety and clinical efficacy evaluation in the calf model for cryptosporidiosis. Significant BKI treatment effects were observed for virtually all clinical and parasitological scoring parameters, including diarrhea severity, oocyst shedding, and overall health. These results provide proof of concept for BKIs as therapeutic drug leads in an animal model for human cryptosporidiosis.

KW - Animal model

KW - Bumped kinase inhibitor

KW - Clinical evaluation

KW - CpCDPK-1

KW - Cryptosporidiosis

KW - Cryptosporidium

KW - Oocyst shedding

KW - Therapeutic

UR - http://www.scopus.com/inward/record.url?scp=85016016118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016016118&partnerID=8YFLogxK

U2 - 10.1093/infdis/jiw488

DO - 10.1093/infdis/jiw488

M3 - Article

C2 - 27923949

AN - SCOPUS:85016016118

VL - 214

SP - 1856

EP - 1864

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 12

ER -